[c09aa8]: / clusters / clusters342final / clust_277.txt

Download this file

18 lines (17 with data), 2.1 kB

 1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
Patients who have had chemotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy within 2 weeks prior to cycle 1 day 1; patients who have had tyrosine kinase inhibitors (such as Braf or MEK inhibitors) within 15 days of cycle 1 day 1
Availability of a frozen biopsy core prior to cycle 1, day 1
Patients must be willing to use the Optune device >= 18 hours/day for at least 23 days in a 28-day cycle, and keep head shaved throughout treatment
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Patients who have not recovered from adverse events to < grade 1 (other than alopecia) due to agents administered more than 3 weeks earlier; however, the following therapies are allowed:* Hormone replacement therapy or oral contraceptives* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)* Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1
Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
If patient is currently on prednisone or other corticosteroids for palliation, the dose must be less than or equal to 10 mg a day or its equivalent dose and it must have been started at least 4 weeks prior to cycle 1 day 1
Patients who have received any other investigational agents within the past 28 days prior to cycle 1 day 1
Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1